Redeye: Lipigon Q1 2024 - Phase II Underway
Redeye comments on Lipigon's Q1 report 2024. Since our last update, patient recruitment to the phase II study of Lipisense has begun.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/